(Q34239867)

31 July 2017

1 reference

title

Prognosis determination in heart failure (English)

1 reference

31 July 2017

1 reference

Eichhorn EJ

1

1 reference

PubMed ID

11334772

31 July 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

American Journal of Medicine

31 July 2017

1 reference

31 July 2017

110 Suppl 7A

1 reference

31 July 2017

14S-36S

1 reference

Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Epidemiology of congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

The incidence and prevalence of congestive heart failure in Rochester, Minnesota.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Prevalence and mortality rate of congestive heart failure in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Effect of a heart failure program on hospitalization frequency and exercise tolerance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Effect of mibefradil, a T-type calcium channel blocker, on morbidity and mortality in moderate to severe congestive heart failure: the MACH-1 study. Mortality Assessment in Congestive Heart Failure Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

The effect of digoxin on mortality and morbidity in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Survival after the onset of congestive heart failure in Framingham Heart Study subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Neurohumoral consequences of vasodilator therapy with hydralazine and nifedipine in severe congestive heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Adverse consequences of high sympathetic nervous activity in the failing human heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Prognosis of congestive heart failure and predictors of mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Heart rate variability in idiopathic dilated cardiomyopathy: characteristics and prognostic value

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Ability of heart rate variability to predict prognosis in patients with advanced congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Prognostic value of heart rate variability in chronic congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Determinants of prognosis in nonischemic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Plasma N-terminal atrial natriuretic factor: a predictor of survival in patients with congestive heart failure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Tumor Necrosis Factor Soluble Receptors in Patients With Various Degrees of Congestive Heart Failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Prognostic value of plasma endothelin-1 in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Plasma endothelin in congestive heart failure: a predictor of cardiac death?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Factors influencing survival and mode of death in severe chronic ischaemic cardiac failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Factors influencing the one-year mortality of dilated cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Prognostic value of dobutamine echocardiography in patients with left ventricular dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Prognostic value of bisoprolol-induced hemodynamic effects in heart failure during the Cardiac Insufficiency BIsoprolol Study (CIBIS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Decreased coronary sinus oxygen content: A predictor of adverse prognosis in patients with severe congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Survival of patients with severe congestive heart failure treated with oral milrinone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: clinical, echocardiographic and hemodynamic correlations and prognostic implications. Heart Muscle Disease Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

QT dispersion and RR variations on 12-lead ECGs in patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Right ventricular ejection fraction: An indicator of increased mortality in patients with congestive heart failure associated with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Correlates and prognostic implication of exercise capacity in chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Role of maximal oxygen consumption in establishment of heart transplant candidacy for heart failure patients with intermediate exercise tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Survival in men with severe chronic left ventricular failure due to either coronary heart disease or idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Clinical determinants of mortality in chronic congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Ambulatory ventricular arrhythmias in patients with heart failure do not specifically predict an increased risk of sudden death. PROMISE (Prospective Randomized Milrinone Survival Evaluation) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Prognosis in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

The effect of treatment on survival in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

The effect of tumor necrosis factor-alpha on cardiac structure and function: a tale of two cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Increased plasma concentrations of endothelin in congestive heart failure in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Endothelin-1 induces hypertrophy with enhanced expression of muscle-specific genes in cultured neonatal rat cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Prognosis in severe heart failure: relation to hemodynamic measurements and ventricular ectopic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Patient characteristics in cases of chronic severe heart failure with different degrees of left ventricular systolic dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Medical therapy can improve the biological properties of the chronically failing heart. A new era in the treatment of heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Predictors of systolic and diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Comparison of left and right ventricular end-systolic pressure-volume relations in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Myocardial energetics in patients with dilated cardiomyopathy. Influence of nitroprusside and enoximone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Myocardial blood flow distribution in patients with ischemic heart disease or dilated cardiomyopathy undergoing heart transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

A biological approach to sudden cardiac death: structure, function and cause

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Racial differences in the outcome of left ventricular dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Racial differences in sensitivity to the negative chronotropic effects of propranolol in healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Racial difference in the relationship of an angiotensin I-converting enzyme gene polymorphism to serum angiotensin I-converting enzyme activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Mode of death in chronic heart failure. A request and proposition for more accurate classification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Arrhythmias and mortality in congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Effect of selective versus nonselective beta blockade on QT dispersion in patients with nonischemic dilated cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Reduction in QT interval dispersion by successful thrombolytic therapy in acute myocardial infarction. TEAM-2 Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

QT dispersion and components of the QT interval in ischaemia and infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

QTc dispersion predicts cardiac mortality in the elderly: the Rotterdam Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

QT interval dispersion as a predictor of arrhythmic events in congestive heart failure. Importance of aetiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

Mechanical circulatory support and cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2898%2900384-2

10.1016/S0002-9343(98)00384-2

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11334772